Table 3.
Shell Composition | Size (nm) | Experimental Model | Drugs |
---|---|---|---|
Molecular Ligands | |||
Curcumin [48,116,117] | 5–122.2 (A) 7–185 (B) 11 (An) |
In vitro In vivo (rat, mousse) |
Lactoferrin, RGE peptide (a specific ligand of NPR-1) |
dimercaptosuccinic acid-DMSA [118] | 4–9 (A) 65–70 (B) |
In vitro In vivo (rat) |
No |
Liposome [47,64,71,101,119,120] | 7–104 (A) 83.2–190 (B) 5–10 (An) 7.4 (Bn) |
In vitro In vivo (rat) |
Paclitaxel, Transactivating-transduction protein, Doxorubicin, Rituximab, Transferrin |
Surfactants | |||
Janus [65] | 90.4 (A) | In vitro | Doxorubicin, folic acid |
Amphiphilic polymer [102] | 10–30 (A) 18–40 (B) |
In vitro In vivo (rat) |
Monocyte-derived-macrophage |
TPGS [75] | 178.6 (A) 29.9 (An) |
In vitro In vivo (mouse) |
No |
D-Alpha-Tocopheryl Polyethylene Glycol Succinate [77] | 8.4 (A) 227.9 (B) |
In vitro | Doxorubicin |
DMAB [75] | 67.1 (A) 29.9 (An) |
In vitro In vivo (mouse) |
No |
Twen 80 [46,49,57,64,77,84] | 8.4–148.7 (A) 140–220 (B) |
In vitro In vivo (rat, mouse) |
Clonazepam, Brain-derived neurotrophic factor, Temozolomide, Doxorubicin, Rituximab |